Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 419

1.

SASLT guidelines: Update in treatment of Hepatitis C virus infection.

Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F.

Saudi J Gastroenterol. 2016 Aug;22 Suppl:S25-57. doi: 10.4103/1319-3767.188067. No abstract available.

2.

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.

de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B.

Front Pharmacol. 2016 Jul 22;7:197. doi: 10.3389/fphar.2016.00197. eCollection 2016.

3.

Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection.

FakhriRavari A, Malakouti M, Brady R.

J Clin Transl Hepatol. 2016 Jun 28;4(2):97-112. doi: 10.14218/JCTH.2016.00007. Epub 2016 Jun 15. Review.

4.

Beneficial therapeutic effects of Nigella sativa and/or Zingiber officinale in HCV patients in Egypt.

Abdel-Moneim A, Morsy BM, Mahmoud AM, Abo-Seif MA, Zanaty MI.

EXCLI J. 2013 Nov 11;12:943-55. eCollection 2013.

5.

Low-dose lipopolysaccharide (LPS) inhibits aggressive and augments depressive behaviours in a chronic mild stress model in mice.

Couch Y, Trofimov A, Markova N, Nikolenko V, Steinbusch HW, Chekhonin V, Schroeter C, Lesch KP, Anthony DC, Strekalova T.

J Neuroinflammation. 2016 May 16;13(1):108. doi: 10.1186/s12974-016-0572-0.

6.

Distribution of Hepatitis C Virus Genotypes in Bahrain.

Janahi EM, Al-Mannai M, Singh H, Jahromi MM.

Hepat Mon. 2015 Dec 7;15(12):e30300. doi: 10.5812/hepatmon.30300. eCollection 2015 Dec.

7.

Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels.

Wu CK, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Lin MT, Yen YH, Hung CH, Hu TH.

PLoS One. 2016 Mar 11;11(3):e0142378. doi: 10.1371/journal.pone.0142378. eCollection 2016.

8.

Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria.

Ogwu-Richard SO, Ojo DA, Akingbade OA, Okonko IO.

Afr Health Sci. 2015 Sep;15(3):719-27. doi: 10.4314/ahs.v15i3.4.

9.

Recent advances in management of the HIV/HCV coinfected patient.

Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD.

Future Virol. 2015;10(8):981-997.

10.

Bibliometric analysis of the top-cited gastroenterology and hepatology articles.

Azer SA, Azer S.

BMJ Open. 2016 Feb 8;6(2):e009889. doi: 10.1136/bmjopen-2015-009889.

11.

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.

Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C.

Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):597-609. doi: 10.1007/s10096-016-2576-1. Epub 2016 Feb 6.

12.

Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors.

Gupta S, Termini JM, Issac B, Guirado E, Stone GW.

PLoS One. 2016 Feb 5;11(2):e0148929. doi: 10.1371/journal.pone.0148929. eCollection 2016.

13.
14.

The role of HCV proteins on treatment outcomes.

Kumthip K, Maneekarn N.

Virol J. 2015 Dec 15;12:217. doi: 10.1186/s12985-015-0450-x.

15.

The hematopoietic regulator, ELF-1, enhances the transcriptional response to Interferon-β of the OAS1 anti-viral gene.

Larsen S, Kawamoto S, Tanuma S, Uchiumi F.

Sci Rep. 2015 Dec 8;5:17497. doi: 10.1038/srep17497.

16.

Hepatitis C virus: A global view.

Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z.

World J Hepatol. 2015 Nov 18;7(26):2676-80. doi: 10.4254/wjh.v7.i26.2676. Review.

17.

Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance.

Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C.

World J Hepatol. 2015 Nov 8;7(25):2590-6. doi: 10.4254/wjh.v7.i25.2590. Review.

18.

Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

Fung J.

World J Hepatol. 2015 Oct 28;7(24):2543-50. doi: 10.4254/wjh.v7.i24.2543. Review.

19.
20.

Analyzing the Effects of Pretreatment Diversity on HCV Drug Treatment Responsiveness Using Bayesian Partition methods.

Fu Y, Chen G, Guo X, Zhang J, Pan Y.

J Bioinform Proteom Rev. 2015;1(1):1-6. Epub 2015 May 12.

Items per page

Supplemental Content

Write to the Help Desk